2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Pathogenesis, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4395 A novel composite score of healthcare resource utilization identifies key risk factors in patients receiving lisocabtagene maraleucel in the outpatient setting

Jennifer J. Huang, MD, PhD, Jenna Voutsinas, MPH2, Ryan Basom3, Ismat Jahan4, Kelly Crebs5, Samuel B Albert6, Alex Susser7, Michelle Ufua8, Dwight Macero9, Christy Khouderchah, PharmD, BCOP10, Leslie Swanson11, Cindy Sidwa12, Andrew J. Portuguese, MD13, Emily C. Liang, MD14, Alexandre V Hirayama, MD15, Zachary Yaffe16, Lorenzo Iovino, MD, PhD17, Edus H. Warren, MD, PhD18, Fei Fei Liu, GDCE, MBA19, Christine Fu, PhD20, Jinender Kumar, MS21, Qian Wu, PhD22, Mazyar Shadman, MD, MPH23, Jordan Gauthier, MD24
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States
10 Fred Hutchinson Cancer Center, Seattle, Washington, United States
11 Fred Hutchinson Cancer Center, Seattle, Washington, United States
12 Fred Hutchinson Cancer Center, Seattle, Washington, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
14 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
15 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
16 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
17 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
18 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
19 Bristol Myers Squibb, Lawrence Township, New Jersey, United States
20 Bristol Myers Squibb, Lawrence Township, New Jersey, United States
21 Bristol Myers Squibb, Lawrence Township, New Jersey, United States
22 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
23 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
24 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States

Background

Many patients who receive lisocabtagene maraleucel (liso-cel) can be managed in the outpatient setting with minimal healthcare resource utilization (HCRU). However, a subset of patients may require hospitalization and interventions such as growth factor support or transfusions, leading to increased HCRU. To identify the key patient and disease characteristics associated with higher HCRU, we developed a novel HCRU composite score (HCS) and comprehensively analyzed factors associated with increased HCS.

Methods

We included all patients who received liso-cel in the outpatient setting at Fred Hutch Cancer Center from 4/2021 to 9/2025. Each intervention (days 0-30 post-infusion) was weighted based on their relative HCRU: 1 or 3 points for each day of acute care or intensive care unit admission, respectively; 0.5 points for each administration of growth factor support or transfusion; and 0.25 points for each outpatient visit. We applied linear univariate regression to identify patient (age, gender, race, ethnicity, ECOG, Cumulative Illness Rating Scale-Geriatric (CIRS-G) comorbidity score, TRANSCEND/TRANSFORM eligibility), disease (type of lymphoma, Ann Arbor staging, extranodal or central nervous system [CNS] involvement), and treatment-related factors (pre-lymphodepletion [LD] laboratory assessments) associated with higher HCS. HCS was log-transformed to account for skew. Factors associated with HCRU in univariate analyses and potential confounders based on clinical considerations were included in the multivariable regression model and with consideration of degrees of freedom.

Results

We identified 125 patients who received liso-cel in the outpatient setting. Median age was 69 years; 62% (n=77) were male. The most common race was White (81%, n=101) followed by Asian (10%, n=13); unknown (3%, n=4); and Black/African American, multiple, and American Indian/Alaska Native (1.6% each, n=2). Six percent (n=8) of patients were Hispanic. Majority of patients had an ECOG of 0 (54%, n=68) and 42% (n=53) an ECOG of 1-3. Most patients had a CIRS-G of 0-6 (77%, n=96) and an HCT-CI score of 0-2 (77%; n=96). Thirty-nine percent of patients were eligible for TRANSCEND and 21% for TRANSFORM.

The HCS showed a right-skewed distribution with the majority of patients (57%, n=71) with an HCS<10 (median HCS, 8; interquartile range, 3-13) consistent with current evidence regarding the safety profile of liso-cel. HCS distribution included <5 (34%, n=42), ≥5 to 10 (23%, n=29), ≥10-20 (35%, n=44), ≥20-40 (7%, n=9), and ≥ 40 (0.8%, n=1).

Univariate analyses demonstrated that patient and disease characteristics such as older age (p=0.019;), ECOG 1-3 (p=0.026), presence of extranodal disease (p=0.007), and CNS involvement (p=0.019) were associated with higher HCS. Pre-LD laboratory assessment such as higher white blood cell count (p=0.032), lower hemoglobin (Hgb) (p<0.001), higher creatinine [Cr] (p=0.038), and higher lactate dehydrogenase (LDH) (p=0.035) were also associated with a higher HCS.

In multivariable analysis (complete-case set, n=98), extranodal disease (p=0.01) and lower pre-LD Hgb (p=0.004) remained independently associated with higher HCS while age (p=0.3), ECOG of 1-3 (p=0.056), and pre-LD Cr (p=0.064) were not statistically significant.

Conclusion

Liso-cel was generally associated with low HCS, with 34% of patients with an HCS<5 and 57% with an HCS<10. Acknowledging limitations of retrospective exploratory analysis and multiple testing limitations, univariate analyses demonstrated that age, ECOG, and factors reflecting more widespread disease as well as anemia, decreased renal function, and increased LDH were associated with increased HCS. Extranodal disease and pre-LD Hgb remained independently associated with higher HCS in multivariable analysis. A better understanding of the characteristics that lead to increased HCRU may guide discussions with patients regarding their expected clinical course, which may include hospital infusions and other interventions such as growth factor injections and infusions.
Jennifer J. Huang, MD, PhD: BMS - Research Funding; BeOne Medicines - Research Funding; AbbVie - Research Funding; Merck - Research Funding; AbbVie - Consultancy (Includes expert testimony)